Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at ESCMID Global (Formerly ECCMID)
Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA
Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China™s National Reimbursement Drug List
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies...
COPENHAGEN, Sept 21 (Reuters) - Novo Holdings, the controlling shareholder in drugmaker Novo Nordisk (NOVOb.CO), on Thursday said it had closed its acquisition of biopharmaceutical company Paratek Pharmaceuticals in a deal valued at $462 million.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital (œGurnet Point) and Novo Holdings A/S (œNovo Holdings) announced today the completion of their acquisition of Paratek...
Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 per Share on...